AUG 22, 2016 6:04 AM PDT

MicroRNA Biomarker for Colon Cancer

WRITTEN BY: Xuan Pham

Just because a chemotherapeutic drug exist does not mean it will work for every patient. There has been no other time when this sentiment has resonated more soundly than now, in the era of personalized medicine.
 
In the case of colorectal cancer, a diagnosis isn’t quite enough, as nearly half of the patients are apparently resistant to the drug regimen commonly used as a first-line defense in this cancer. "The challenge is that we do not know beforehand in which 50% the treatment will work. This means we have to treat all patients in the same way - including the 50% who do not benefit, " said Claus Lindbjerg Andersen, professor at the Aarhus University Hospital who led the research efforts to find new biomarkers for colorectal cancer.
 

Image credit: Pixabay.com


 
Colorectal cancer, also known as colon cancer or bowel cancer, is the third most commonly diagnosed cancer type in the world. The cancer usually begins as small, benign lumps of cells that form polyps in the colon. Without proper removal, these polyps can turn cancerous and cause symptoms such as abdomen pain, rectal bleeding, weakness, and fatigue. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2?million new cases and 1.1?million deaths by 2030.
 
The goal was to better predict which set of patients will respond to Oxaliplatin, a chemotherapy drug widely used in colon cancer. By looking at the genetic profile of patients treated with oxaliplatin, the researchers found differences in those who seemed to respond to the drug, versus those who seemed to be resistant to the treatment.
 
The difference? A microRNA molecule known as miR-635-3p. The presence of this molecule appeared to prevent oxaliplatin from killing the colorectal cancer cells. Thus, those with this biomarker are unlikely to benefit from oxaliplatin. In fact, the team found that,"Patients with tumors positive for the molecule actually have a six times higher risk of being treatment-resistant than other patients,” said Mads Heilskov Rasmussen, first author of the paper.
 
Current detection methods for colorectal cancer include invasive colonoscopy procedures that check for the presence of pre-cancerous polyps. When polyps are found, physicians can remove it before they turn into cancer. Another source of detection is through screening patients for commonly mutated genes that are associated with colorectal cancer. But detection is nowhere enough if the treatments offered to patients have a high chance of not working.
 

 
With the microRNA biomarker, doctors could screen colorectal patients and identify those who may or may not respond to the oxaliplatin ahead of treatment initiation. This would spare patients who express the microRNA biomarker from undergoing fruitless treatments, in favor of those that might have a better chance of being effective.
 
"Our discovery also opens up for development of new treatment strategies as we have shown that if the microRNA is eliminated from the tumor, the effect of Oxaliplatin is restored" says Claus Lindbjerg Andersen. Accordingly, combination therapies could be a way forward.

Additional source: Aarhus University Hospital

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 10, 2021
Cancer
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
APR 10, 2021
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
New findings support the administration of a CD40 immune-stimulating drug to early-stage pancreatic cancer patients in a ...
APR 21, 2021
Cancer
Native shrub could fight undruggable cancer gene
APR 21, 2021
Native shrub could fight undruggable cancer gene
New research published in the Journal of the American Chemical Society reports on another cancer-fighting development, t ...
MAY 13, 2021
Cancer
Ovarian cancer screening doesn't save lives, reports new study
MAY 13, 2021
Ovarian cancer screening doesn't save lives, reports new study
New research published in the journal The Lancet highlights the eagerly awaited results of the UK Collaborative Trial of ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
JUL 22, 2021
Cell & Molecular Biology
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
JUL 22, 2021
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
To study biology, researchers need models. Once those models might have been a bit limited to organisms like rats or mic ...
JUL 26, 2021
Genetics & Genomics
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
JUL 26, 2021
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
Many types of cells have to be replenished continuously throughout our lives, and the genome in the nucleus of those cel ...
Loading Comments...